GXV813 compared with placebo in hospitalized adults with schizophrenia
Tests GXV813 against placebo in hospitalized adults with an acute schizophrenia episode.
Key facts
- Who runs it
- Novartis Pharma AG
- Where
- Burgas, Haskovo, Kazanlik, Lovech, Plovdiv, Sliven, Sofia, Veliko Tirnovo, and Vratsa, BulgariaSee the 10 sites
- Trial code
- Registry title
- A Phase 2 Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults with Schizophrenia (STAR-1)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 42 people, planned
- Started
- 22 Jun 2026
- Expected to end
- 27 Apr 2027
- Type of study
- Interventional
- Record updated
- 29 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with schizophrenia who are having an acute flare-up and need to stay in hospital for the whole study.
- Age
- 18 to 65 years at screening (the record's age fields say 18 to 64 years).
- Sex
- All sexes can join.
- Disease stage
- Schizophrenia diagnosed by DSM-5 criteria, in an acute worsening that began less than 2 months before screening. Needs hospital care; if already in hospital, for less than 2 weeks for this episode. PANSS total score between 80 and 120.
- Earlier treatment
- People with no response to two adequate courses of antipsychotic medicine, or earlier clozapine for treatment-resistant schizophrenia, cannot join. A long-acting injectable antipsychotic must not have been given for at least 12 weeks (24 weeks for INVEGA TRINZA®) before baseline.
Main reasons for not taking part
- Any main DSM-5 disorder other than schizophrenia in the 12 months before screening
- History of no response to two adequate antipsychotic courses, or earlier clozapine for treatment-resistant schizophrenia
- Needing drugs that are moderate or strong CYP3A4 inhibitors or inducers
- Long-acting injectable antipsychotic given too recently (less than 12 weeks, or 24 weeks for INVEGA TRINZA®, before baseline)
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Participant is aged 18 to 65 years, inclusive, at screening
- Participant is capable of providing informed consent
- Participant has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the DSM-5 (American Psychiatric Association 2013) criteria and confirmed by Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT)
- Participant is willing and able to be confined to an inpatient setting for the study duration (except for the follow-up period), follow instructions, and comply with the protocol requirements
- Participant is experiencing an acute exacerbation with onset less than 2 months before screening a. The participant requires hospitalization for this acute exacerbation or relapse of symptoms b. If already an inpatient at screening, has been hospitalized for less than 2 weeks for the current exacerbation at the time of screening
- Positive and Negative Syndrome Scale total score between 80 and 120, inclusive, at screening a. Score of ≥ 4 (moderate or greater) for ≥ 2 of the following Positive Scale (P) items: 1. Item 1 (P1; delusions) 2. Item 2 (P2; conceptual disorganization) 3. Item 3 (P3; hallucinatory behavior) 4. Item 6 (P6; suspiciousness/persecution)
Who cannot take part
- Any primary DSM-5 disorder other than schizophrenia within 12 months before screening (confirmed using Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID- 5-CT) at screening)
- History of treatment resistance to antipsychotic medications defined as no response to two adequate courses of pharmacotherapy or previous clozapine treatment for treatment-resistant schizophrenia
- Participants who need to be treated with drugs that are known to be moderate and strong CYP3A4 inhibitors and inducers will be excluded
- Participants taking a long-acting injectable antipsychotic could not have received a dose of medication for at least 12 weeks (24 weeks for INVEGA TRINZA®) before baseline
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Bulgaria
- Center For Mental Health Prof. Dr. Ivan Temkov Burgas EOODBurgas, BulgariaTaking people
- Mental Health Center - Haskovo EOODHaskovo, BulgariaTaking people
- Multiprofile Hospital For Active Treatment Dr. Hristo Stambolski EOODKazanlik, BulgariaTaking people
- State Psychiatric Hospital - LovechLovech, BulgariaTaking people
- University Multiprofile Hospital For Active Treatment Saint Georgi EADPlovdiv, BulgariaTaking people
- MBAL Dr. Ivan Seliminski Sliven ADSliven, BulgariaTaking people
- Alexandrovska University HospitalSofia, BulgariaTaking people
- Center For Mental Health Prof. N. Shipkovenski EOODSofia, BulgariaTaking people
- Center Za Psihichno Zdrave Veliko Tarnovo EOODVeliko Tirnovo, BulgariaTaking people
- Center For Mental Health Vratsa EOODVratsa, BulgariaTaking people
About the trial
What the trial wants to find out
To assess the efficacy of GXV813 compared to placebo on positive and negative symptoms in adult inpatients with schizophrenia diagnosed according to DSM-5 criteria experiencing an acute episode
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 2a, Randomized, Participant- and Investigator blinded, Parallel-group, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults with DSM-5 Schizophrenia (STAR-1)
- Plain-language title
- GXV813 compared with placebo in hospitalized adults with schizophreniaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2025-524058-32-00, who can take part
- Record updated
- 29 April 2026